LeMaitre Vascular Q3 sales slightly beat estimates on EMEA performance
Overview
U.S. vascular device maker's Q3 sales rose 11%, slightly beating analyst expectations
Company acquired B. Braun vascular assets, expanding product portfolio outside North America
Outlook
LeMaitre sees Q4 2026 sales of $69.9 mln to $71.9 mln
Company expects full-year 2026 sales of $274.8 mln to $276.8 mln
LeMaitre forecasts Q4 2026 EPS of $0.70 to $0.75 and full-year EPS of $2.77 to $2.82
Result Drivers
PRODUCT SEGMENTS - Grafts and shunts drove Q3 growth, with graft sales up 20% and shunt sales up 14%
PRICING AND VOLUME - Organic sales growth was driven by a 7% increase in average selling prices and a 5% rise in units sold
REGIONAL PERFORMANCE - EMEA sales increased 18%, Americas 9%, and APAC 5%
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Slight Beat* | $67.97 mln | $67.39 mln (8 Analysts) |
Q3 Net Income | $15.02 mln | ||
Q3 Gross Profit | $48.7 mln | ||
Q3 Income From Operations | $17.7 mln | ||
Q3 Pretax Profit | $19.67 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for LeMaitre Vascular, Inc. is $100.00, about 24.1% above its November 3 closing price of $80.60
The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 32 three months ago
Reuters Recommended Reads
Nov 2 - SI-BONE Q3 revenue rises 14.5%, slightly beats estimates
Nov 4 - Zimmer Biomet Q3 sales beat estimates, raises FY outlook
Nov 3 - AtriCure Q3 revenue beats expectations on strong sales of pain management and appendage devices
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)